Advancing RNA Excellence Through Shared Intelligence and Insights
Together, We Discover, Disseminate, and Drive Innovation in RNA Therapeutics
Registration is NOW OPEN
Secure Up to $1200 in Savings with Our Launch Price!
Speaker Interviews
RNA Therapeutics and Partnerships: Novo Nordisk's Approach to Innovation
Revolutionizing RNA Therapeutics: La Jolla Labs' AI-Powered Platform Transforms Drug Discovery
Session Spotlights
Progressing mRNA-based Therapeutics and Vaccines to Combat Cancer
- This session examines industry pathways for advancing personalized cancer mRNA vaccines, comparing allogenic versus autologous approaches and addressing delivery challenges.
- Experts review progress in mRNA-encoded immunotherapies and provide insights into future developments with projected 2026 milestones.
Applying An Intricate RNA Design Platform for Immunomodulation, Next-Gen mRNA Vaccines and RNA-based Protein Therapeutics
- This session examines an innovative RNA design platform that enables creation of optimized RNA sequences for immunomodulation, enhancing efficacy of next-generation mRNA vaccines and RNA-based protein therapeutics.
Scaling Oligo-based Therapeutics with Innovation at the forefront
- This session explores cutting-edge advancements in oligonucleotide synthesis, manufacturing, and delivery technologies.
- Industry experts discuss strategies for scaling oligo-based therapeutics from research to commercial production, examining innovative approaches to improve efficacy, safety, and accessibility of siRNAs and antisense oligonucleotides.
Join the community
Follow us on LinkedIn for the latest RNA Leaders updates and news.
Top Companies joining us at RNA Leaders USA
With roots dating back to 1758, Novartis has evolved into a healthcare powerhouse operating in 155 countries. Their strategic pivot toward RNA technologies represents a significant expansion of their therapeutic arsenal. Malgorzata Gonciarz, Global Head of xRNA Therapeutics and Christopher O'Donnell, Global Head of Cardiovascular & Metaboli at Novartis will be joining us at RNA Leaders USA to touch on fostering partnerships within RNA Pharma and Industry and regulatory challenges on Oligonucleotide Development.
This British-Swedish multinational, formed through the 1999 merger of Astra AB and Zeneca Group, has become a frontrunner in RNA delivery innovation. Their Advanced Drug Delivery unit tackles one of RNA therapeutics' greatest challenges: targeted cellular delivery. Annette Bak, who leads this division, will present their proprietary delivery technologies that aim to expand RNA medicines beyond liver applications.
Established in Denmark in 1923, Novo Nordisk transformed from an insulin producer to a diversified healthcare leader. Their recent expansion into nucleic acid therapeutics marks a strategic evolution beyond their traditional strengths. At RNA Leaders USA, Shanthi Ganesh, Senior Scientific Director of Global Nucleic Acid Therapies, will highlight their novel RNAi technology that silences PD-L1 in tumor-associated immune cells, showing promise in remodelling tumor microenvironments and overcoming immunotherapy resistance in preclinical models.
Key topics at RNA Leaders USA
What are the latest innovations in RNA delivery technologies?
RNA delivery technologies have evolved significantly, with a notable shift from passive to active delivery systems that enable precise targeting of specific tissues and cell types. These advancements are critical for improving the efficacy and safety profiles of RNA therapeutics while expanding their application to previously inaccessible disease targets. Leading companies are reporting breakthrough results with hybrid delivery systems that combine the advantages of multiple approaches.
What breakthroughs are occurring in oligonucleotide-based RNA therapeutics?
Oligonucleotide-based therapeutics are experiencing a renaissance with novel chemical modifications, improved delivery systems, and expanded targeting capabilities. Recent innovations have significantly enhanced the stability, tissue penetration, and target engagement of antisense oligonucleotides (ASOs) and siRNAs, leading to improved clinical outcomes and reduced dosing frequency. These advancements are expanding the range of diseases that can be effectively addressed with oligonucleotide approaches.
How are next-generation RNA technologies transforming the therapeutic landscape?
Next-generation RNA technologies including circular RNAs, small activating RNAs, and RNA editing approaches are creating entirely new therapeutic modalities with unique advantages. These innovative platforms enable precise manipulation of gene expression without permanent genetic changes, offering potential solutions for diseases that have been challenging to address with traditional approaches. Early clinical results are demonstrating promising efficacy with favorable safety profiles.
Discover our Next Generation RNA track to find out more about the latest innovations within the industry.
What analytical advances are improving RNA therapeutic development?
Comprehensive analytical platforms are revolutionizing RNA therapeutic development by enabling more detailed characterization of potency, safety, and purity. Advanced techniques for assessing RNA structure, modifications, and impurities are providing deeper insights into critical quality attributes that influence therapeutic performance. These analytical capabilities are accelerating development timelines while enhancing regulatory confidence in RNA-based medicines.
How are manufacturing processes evolving to support commercial-scale RNA production?
Manufacturing innovations are addressing the unique challenges of RNA production at commercial scale, with significant advancements in enzymatic synthesis, purification technologies, and process intensification. These developments are dramatically reducing production costs while improving quality and consistency, enabling broader application of RNA therapeutics across diverse disease areas and patient populations.
